Alkermes plc. Files 8-K: Regulation FD & Financials

Ticker: ALKS · Form: 8-K · Filed: 2025-09-08T00:00:00.000Z

Sentiment: neutral

Topics: regulation-fd, financials, reporting

TL;DR

Alkermes filed an 8-K on 9/8/25 for Reg FD and financials. Standard update.

AI Summary

Alkermes plc. filed an 8-K on September 8, 2025, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at Connaught House, 1 Burlington Road, Dublin 4, Ireland, and its primary business in Pharmaceutical Preparations.

Why It Matters

This filing provides an update on Alkermes' regulatory disclosures and financial reporting, which are crucial for investors to assess the company's current status and compliance.

Risk Assessment

Risk Level: low — This is a routine filing for an 8-K, indicating standard corporate reporting rather than a material event.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Alkermes plc.?

This 8-K filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically covering Regulation FD Disclosure and Financial Statements and Exhibits.

When was this 8-K filing submitted by Alkermes plc.?

The filing was made on September 8, 2025.

Where are Alkermes plc.'s principal executive offices located?

Alkermes plc.'s principal executive offices are located at Connaught House, 1 Burlington Road, Dublin 4, Ireland.

What is Alkermes plc.'s Standard Industrial Classification code?

Alkermes plc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

What is the Commission File Number for Alkermes plc.?

The Commission File Number for Alkermes plc. is 001-35299.

Filing Stats: 582 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-09-08 09:15:27

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 8, 2025, in connection with its participation at the World Sleep Congress taking place September 5-10, 2025, Alkermes plc (the "Company") issued a press release announcing detailed safety and efficacy results from Vibrance-1, the Company's phase 2 study evaluating the safety and efficacy of alixorexton (formerly referred to as ALKS 2680) compared to placebo in patients with narcolepsy type 1. Copies of the Company's press release and related investor presentation and scientific presentations are furnished herewith as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated herein by reference. The information in this Item 7.01, and in Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 furnished herewith, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Sta tements and Exhibits

Item 9.01 Financial Sta tements and Exhibits. (d) Exhibits EXHIBIT INDEX Exhibit No. Description 99.1 Press release issued by Alkermes plc dated September 8, 2025. 99.2 Investor presentation of Alkermes plc displayed on September 8, 2025. 99.3 Scientific presentations of Alkermes plc displayed on September 8, 2025. 104 Cover page interactive data file (embedded within the Inline XBRL document). 2 SIGNA TURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALKERMES PLC Date: September 8, 2025 By: /s/ David J. Gaffin David J. Gaffin Secretary 3

View on Read The Filing